Agents Affecting Blood Clotting. Anticoagulant Agents Prevent the extension and formation of clots. Inhibition by interference with the ‘coagulation cascade’

Slides:



Advertisements
Similar presentations
Chapter 19 Hematologic Products.
Advertisements

Drugs for Coagulation Disorders
Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria
Drugs for Coagulation Disorders Andrew N. Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 8, 2008
Chapter 19 Agents Affecting Blood Clotting. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Blood.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
STROKE & PREGNANCY By Judith Barnaby, Stroke CNS Reviewed by Dr. Bayer, Stroke Neurologist, St. Michael’s Hospital.
Pathophysiology of Thrombosis Thrombosis and Thrombolysis in Acute Coronary Syndromes.
Thromboembolic Disorders and Related Medications Nsg 106 Pharmacotherapeutics.
PTP 546 Module 6 Cardiovascular Pharmacology: Part II Jayne Hansche Lobert, MS, RN, ACNS-BC, NP 1Lobert.
1 Disseminated Intravascular Coagulation Paramedic Program Chemeketa Community College.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Anticoagulation in the Acute Care Population Aimee Ring PT, DPT, GCS.
Pulmonary Embolism. Definition: Sudden lodgment of a blood clot in a pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma.
Hemostasis and Blood Coagulation
ANTICOAGULANT BY :DR ISRAA OMAR.
Dr Mahvash Khan MBBS, MPhil. ◦ Occurs inside the blood vessels, it is also called fibrinolysis ◦ Occurs due to a substance known as plasmin (fibrinolysin)
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Drugs used in coagulation disorders By S.Bohlooli, Ph.D.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar Dr.Abdul latif Mahesar 1.
Study Guide Guide for Patients Undergoing Anticoagulant Therapy.
Anticoagulants 1. Parenteral Anticoagulants e.g. heparin
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
Thrombolytic drugs BY :DR. ISRAA OMAR.
CARDIOVASCULAR MODULE: DEEP VENOUS THROMBOSIS THROMBOPHLEBITIS Adult Medical-Surgical Nursing.
Presented by: Passant Mounir Nagy Under the supervision of: Prof. Dr/ Seham Hafez.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Developed by: Dawn Johnson, RN, MSN, Ed.  Internally and externally  Prevent bleeding from wounds which could lead to shock or even death.
Anticoagulations and Coagulants
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Fibrinolytics, anticoagulants and antiplatelets
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar.
THROMBOLYTIC DRUGS Pathophysiologic Rationale
Blood coagulation is a complex process that involves vasoconstriction, platelet clumping or aggregation, and a cascade of clotting factors produced in.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar
Agents Affecting Blood Clotting
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Chapter 19 Agents affecting Blood Clotting. Blood Clotting p461 Clotting is necessary to prevent fatal loss of blood from a minor injury Thromboemboli.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar Dr
Anticoagulants, Antiplatelets, and Thrombolytics
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Course Lecturer: Imon Rahman
Thrombosis and Embolism. Thrombus Thrombus: a blood clot occurring in a vessel or the heart Thrombus: a blood clot occurring in a vessel or the heart.
Thrombosis and Embolism. Thrombus Thrombus: a blood clot occurring in a vessel or the heart Thrombus: a blood clot occurring in a vessel or the heart.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
Chapter 23 Thrombo-Embolic diseases
23 Anticoagulants.
Bleeding disorders Deficiency of any of the clotting factors leads to excessive bleeding Most common and important bleeding disorders are due Vitamin K.
Blood/Blood Formation
Anticoagulants, Antiplatelets, and Thrombolytics
Anistreplase Drugbank ID : DB00029
Management of ST-Elevation Myocardial Infarction
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar Dr
Fibrinolytic Drugs (Thrombolytic Drugs )
The normal haemostasis process involves three stages: 1
Coagulation Disorders
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Chapter 17 Hematologic Products
Disseminated intravascular coagulation (DIC)
23 Anticoagulants.
Drugs Affecting Blood.
Anticoagulants.
When a blood vessel is injured, a series of events occur to form a clot and stop the bleeding. This process is called hemostasis. It involves a complex.
FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.
Presentation transcript:

Agents Affecting Blood Clotting

Anticoagulant Agents Prevent the extension and formation of clots. Inhibition by interference with the ‘coagulation cascade’ – Drug Specific Usage – Thrombosis – Pulmonary Embolism – Myocardial Infarction

Clotting Cascade

Thromboembolism Consequences of Pulmonary Embolism - increased alveolar dead space, - pneumoconstriction - hypoxemia - hyperventilation. - regional loss of surfactant - pulmonary infarction.

Pulmonary emboli – Thrombus originating in the lower extremities  travels to the lung – lodges at the bifurcation of the main pulmonary artery/lobar branches  causes hemodynamic compromise i.e. - occlusion of smaller vessels in the lung periphery – produces pleuritic chest pain

Diagnosis of PE Missed in approximately 400,000 patients in the United States per year Approximately 100,000 deaths could be prevented Death from a massive PE is second only to the cardiac deaths - 10% of patients who develop PE die within the first hour -30% die subsequently from recurrent embolism  Anticoagulant treatment decreases the mortality rate to less than 5%.

Heparin Inhibits thrombin from converting to fibrinogen Also inactivates factors IXa, Xa, XIa and XIIa Inactivated by stomach acids so must be given parentally, not IM Prevention of a stable fibrin clot Metabolized in the liver; Excreted by the kidneys.

Additional Uses Out of body experiences (!) – Used to prevent clotting whenever the patient’s blood must circulate outside the body Used whenever prolonged coagulation is desired. – Central IV lines – Arterial lines – Some surgeries usually orthopedic DIC (Disseminated Intravascular Clotting) – Although bleeding is a symptom, the cause is hypercoagulation

Heparin Adverse Reactions: – Hemorrhage – Prolonged clotting time Bleeding gums Bloody noses Multiple bruises Black Stools Thrombocytopenia (low platelets) Necrosis of the skin Hypersensitivity reaction

Special Nursing Care Never give Heparin IM When injecting heparin subcutaneously, inject into the abdomen with a small gauge needle at a 90-degree angle Do not aspirate or rub the injection site

Heparin Drug Interactions Act synergistically with oral anticoagulants or antiplatelet drugs Risk of bleeding increases with usage of NSAIDs, Iron dextran, and ASA Drugs that inactivate or antagonize heparin Box 19-2 pg. 464 (Pharmocology) Protamine sulfate and administration of FFP are used as antidotes

Low Molecular Weight Anticoagulant Example: Enoxaparim (Lovenox) Chemically altered Heparin, actually broken down into smaller compounds. Used in prevention of thrombus especially after surgery. Prolonged circulating half life Blocks Xa factor, doesn’t affect fibrin formation

Oral Anticoagulants Warfarin (Coumadin) – Inhibits blood clotting by interfering with the synthesis of vitamin K-dependent clotting factors, VII, IX and X (which are formed in the liver) –  May be started concomitantly with Heparin therapy – Sometimes combined with antiplatelet drug such as aspirin, clopidogrel or dipyridamole to decrease arterial clotting.

Warfarin: Adverse Reactions Primary adverse reaction is minor bleeding Severe bleeding can occur, primarily in the GI tract or brain Bruises and hematomas may form at puncture sites (IV, Blood Gases, Lab draw) Necrosis or gangrene or the skin Can be reversed with vitamin K (phytonadione) and FFP

Drug Interactions Box 19-3, pg. 466, (Pharmacology Book) Quite the list! Important for patient teaching

Drug Interactions Drugs metabolized by the liver may increase or decrease the effectiveness of warfarin. – Box 19-4, pg. 467, (Pharmacology)  A diet high in vitamin K reduces the effectiveness of oral anticoagulants The risk of phenytoin (Dilantin) toxicity increases when phenytoin is taken with warfarin. Alcohol increases the risk of bleeding - especially chronic and acute alcohol poisoning.

Antiplatelet Agents Action: inhibit the aggregation of platelets – Prevent arterial thromboembolism – Target population: patients at risk for MI, stroke and arteriosclerosis Examples – Aspirin – Clopidogrel bisulfate (Plavix)

Antiplatelet Agents Uses – Useful in treating clients who have experienced CVAs or MI – Evidence suggests these agents may prevent recurrence Remember some drugs or herbs can induce bleeding or delay coagulation time (Box 19-1, pg 464, Pharmacology Book)

Thrombolytic Agents Action – Convert plasminogen to enzyme fibrinolysin; fibrinolysin dissolves clots Example – Streptokinase (IV) Pharmacokinetics – Cleared primarily by the liver Caution – Hemorrhage Uses – Used in an acute or emergency situation to dissolve a preexisting clot or thrombus

Tissue Plasminogen Activator (TPA) Thrombolytic brought to you by DNA technology Example: Activase – Effectiveness is dependent on how soon it is administered. – Within 6 hours of an MI, 71% of clients had improvement Side Effects: internal bleeding usually GI, GU, brain or retroperitoneal

Contraindications with thrombolytic drugs Active internal bleeding Intracranial neoplasm AV Malformation Aneurysm Severe uncontrolled hypertension History of recent stroke (within 2 months) Subarachnoid hemorrhage Bleeding Diathesis e.g. hemophilia Intraspinal or intracranial trauma Surgery within 2 months.

Precautions with Thrombolytic Drugs Can be used but watch closely – Undergone organ biopsy – Traumatic injury – GI or GU bleeding – Cerebrovascular diseases – Hypertension – Mitral stenosis or fibrillation that may lead to left-sided thrombus – Acute pericardiditis or endocardiditc – Septic thrombophlebitis – Diabetic retinopathy – Anticoagulantion therapy – Pregnancy – < 10 days postpartum – lactating

Nursing Interventions Important role in the health and well-being of clients – Education – S/Sx of bleeding – Bleeding from the nose or gums – Vital signs Weak, rapid pulse rate and restlessness are usually the first signs of shock.

Nursing Interventions Client education: – Advise to avoid situations that could lead to trauma – Talk with PMD before adding for subtracting any drug from their treatment program – Drastic changes in diet, laxatives, and mineral oil should be avoided – Identification and information about treatment should always be carried and/or a Medic Alert tag worn – Women on anticoagulants considering pregnancy must be referred to an obstetrician